Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration

PLoS Pathogens

Volumn 11, Issue 7, 2015, Pages

  Pizzato, Massimo ^a,b   McCauley, Sean Matthew ^c   Neagu, Martha R ^a   Pertel, Thomas ^a   Firrito, Claudia ^a   Ziglio, Serena ^b   Dauphin, Ann ^c   Zufferey, Madeleine ^a   Berthoux, Lionel ^d   Luban, Jeremy ^a,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF TRENTO   (Italy)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TRIPARTITE MOTIF PROTEIN 5; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINEAGE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HETEROKARYON; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE CONTRAST MICROSCOPY; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; SYNAPTIC TRANSMISSION; ANIMAL; CELL LINE; DENDRITIC CELL; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOLOGY; MICROBIOLOGY; MONONUCLEAR CELL; T LYMPHOCYTE; VIROLOGY; VIRUS CAPSID; VIRUS DNA CELL DNA INTERACTION;

AVIAN LEUKOSIS VIRUS; CERCOCEBUS TORQUATUS ATYS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MACACA MULATTA; MIRIDAE; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CAPSID; CELL LINE; DENDRITIC CELLS; HIV-2; HUMANS; LEUKOCYTES, MONONUCLEAR; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIRUS INTEGRATION;

EID: 84938809010     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005050     Document Type: Article

References (109)

1. Sharp PM, Hahn BH, (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1: a006841. doi: 10.1101/cshperspect.a006841 22229120
2. Sharp PM, Hahn BH, (2010) The evolution of HIV-1 and the origin of AIDS. Philosophical Transactions of the Royal Society B: Biological Sciences 365: 2487–2494. doi: 10.1098/rstb.2010.0031 20643738
3. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, et al. (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436–441. doi: 10.1038/17130 9989410
4. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, et al. (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313: 523–526. doi: 10.1126/science.1126531 16728595
5. Plantier J-C, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, et al. (2009) A new human immunodeficiency virus derived from gorillas. Nat Med 15: 871–872. doi: 10.1038/nm.2016 19648927
6. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, et al. (2006) Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 444: 164. doi: 10.1038/444164a 17093443
7. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, et al. (2003) Hybrid origin of SIV in chimpanzees. Science 300: 1713. doi: 10.1126/science.1080657 12805540
8. Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, et al. (2009) Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460: 515–519. doi: 10.1038/nature08200 19626114
9. Clavel F, Guyader M, Guetard D, Sallé M, Montagnier L, et al. (1986) Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324: 691–695. doi: 10.1038/324691a0 3025743
10. Damond F, Worobey M, Campa P, Farfara I, Colin G, et al. (2004) Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 20: 666–672. doi: 10.1089/0889222041217392 15242544
11. Gao F, Yue L, Robertson DL, Hill SC, Hui H, et al. (1994) Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 68: 7433–7447. 7933127
12. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR, (1989) An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339: 389–392. doi: 10.1038/339389a0 2786147
13. Apetrei C, Kaur A, Lerche NW, Metzger M, Pandrea I, et al. (2005) Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol 79: 8991–9005. doi: 10.1128/JVI.79.14.8991–9005.2005 15994793
14. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, et al. (1985) Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 230: 71–73. 2412295
15. Ayouba A, Akoua-Koffi C, Calvignac-Spencer S, Esteban A, Locatelli S, et al. (2013) Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d'Ivoire. AIDS 27: 2488–2491. doi: 10.1097/01.aids.0000432443.22684.50 23939239
16. Goff SP, (2004) Retrovirus restriction factors. Mol Cell 16: 849–859. doi: 10.1016/j.molcel.2004.12.001 15610729
17. Luban J, (2007) Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 81: 1054–1061. doi: 10.1128/JVI.01519-06 16956947
18. Nisole S, Stoye JP, Saïb A, (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799–808. doi: 10.1038/nrmicro1248 16175175
19. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, et al. (2005) Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 79: 3930–3937. doi: 10.1128/JVI.79.7.3930–3937.2005 15767395
20. Si Z, Vandegraaff N, O'Huigin C, Song B, Yuan W, et al. (2006) Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci USA 103: 7454–7459. doi: 10.1073/pnas.0600771103 16648259
21. Ylinen LMJ, Keckesova Z, Webb BLJ, Gifford RJM, Smith TPL, et al. (2006) Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J Virol 80: 7332–7338. doi: 10.1128/JVI.00516-06 16840314
22. Schaller T, Hué S, Towers GJ, (2007) An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 proteins. J Virol 81: 11713–11721. doi: 10.1128/JVI.01468-07 17728224
23. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848–853. doi: 10.1038/nature02343 14985764
24. Campbell EM, Perez O, Anderson JL, Hope TJ, (2008) Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 180: 549–561. doi: 10.1083/jcb.200706154 18250195
25. Li X, Li Y, Stremlau M, Yuan W, Song B, et al. (2006) Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. J Virol 80: 6198–6206. doi: 10.1128/JVI.00283-06 16775307
26. Sebastian S, Luban J, (2005) TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2: 40. doi: 10.1186/1742-4690-2-40 15967037
27. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 103: 5514–5519. doi: 10.1073/pnas.0509996103 16540544
28. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, et al. (2006) Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 80: 9754–9760. doi: 10.1128/JVI.01052-06 16973579
29. Rold CJ, Aiken C, (2008) Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog 4: e1000074. doi: 10.1371/journal.ppat.1000074 18497858
30. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ, (2006) Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 103: 7465–7470. doi: 10.1073/pnas.0510483103 16648264
31. Berthoux L, Sebastian S, Sokolskaja E, Luban J, (2004) Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol 78: 11739–11750. doi: 10.1128/JVI.78.21.11739–11750.2004 15479815
32. Ylinen LMJ, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ, (2005) Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol 79: 11580–11587. doi: 10.1128/JVI.79.18.11580–11587.2005 16140735
33. Ohkura S, Yap MW, Sheldon T, Stoye JP, (2006) All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. J Virol 80: 8554–8565. doi: 10.1128/JVI.00688-06 16912305
34. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD, (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA 101: 10774–10779. doi: 10.1073/pnas.0402361101 15249685
35. Keckesova Z, Ylinen LMJ, Towers GJ, (2004) The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 101: 10780–10785. doi: 10.1073/pnas.0402474101 15249687
36. Yap MW, Nisole S, Lynch C, Stoye JP, (2004) Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 101: 10786–10791. doi: 10.1073/pnas.0402876101 15249690
37. Hatziioannou T, Cowan S, Schwedler von UK, Sundquist WI, Bieniasz PD, (2004) Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J Virol 78: 6005–6012. doi: 10.1128/JVI.78.11.6005–6012.2004 15140998
38. Stremlau M, Perron M, Welikala S, Sodroski J, (2005) Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139–3145. doi: 10.1128/JVI.79.5.3139–3145.2005 15709033
39. Yap MW, Nisole S, Stoye JP, (2005) A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15: 73–78. doi: 10.1016/j.cub.2004.12.042 15649369
40. Besnier C, Takeuchi Y, Towers G, (2002) Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 99: 11920–11925. doi: 10.1073/pnas.172384599 12154231
41. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ, (2003) Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J 22: 385–394. doi: 10.1093/emboj/cdg042 12554640
42. Münk C, Brandt SM, Lucero G, Landau NR, (2002) A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 99: 13843–13848. doi: 10.1073/pnas.212400099 12368468
43. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Göttlinger HG, et al. (2002) Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 99: 11914–11919. doi: 10.1073/pnas.162299499 12154227
44. Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, et al. (1999) Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 73: 10020–10028. 10559316
45. Sayah DM, Sokolskaja E, Berthoux L, Luban J, (2004) Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430: 569–573. doi: 10.1038/nature02777 15243629
46. Lai RPJ, Yan J, Heeney J, McClure MO, Göttlinger H, et al. (2011) Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog 7: e1002442. doi: 10.1371/journal.ppat.1002442 22194689
47. Sebastian S, Sokolskaja E, Luban J, (2006) Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol 80: 2051–2054. doi: 10.1128/JVI.80.4.2051–2054.2006 16439561
48. Pertel T, Hausmann S, Morger D, Züger S, Guerra J, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361–365. doi: 10.1038/nature09976 21512573
49. Pertel T, Reinhard C, Luban J, (2011) Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology 8: 49. doi: 10.1186/1742-4690-8-49 21696578
50. Reinhard C, Bottinelli D, Kim B, Luban J, (2014) Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration. Retrovirology 11: 12. doi: 10.1186/1742-4690-11-12 24485168
51. Apetrei C, Lerche NW, Pandrea I, Gormus B, Silvestri G, et al. (2006) Kuru experiments triggered the emergence of pathogenic SIVmac. AIDS 20: 317–321. doi: 10.1097/01.aids.0000206498.71041.0e 16439864
52. Ling B, Apetrei C, Pandrea I, Veazey RS, Lackner AA, et al. (2004) Classic AIDS in a sooty mangabey after an 18-year natural infection. J Virol 78: 8902–8908. doi: 10.1128/JVI.78.16.8902–8908.2004 15280498
53. Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, et al. (1997) A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol 71: 1608–1620. 8995688
54. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. (2010) TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 8. doi: 10.1371/journal.pbio.1000462
55. Liu Z, Pan Q, Ding S, Qian J, Xu F, et al. (2013) The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14: 398–410. doi: 10.1016/j.chom.2013.08.015 24055605
56. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, et al. (2013) Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502: 559–562. doi: 10.1038/nature12542 24048477
57. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, et al. (2013) MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. doi: 10.1038/nature12653
58. Grütter MG, Luban J, (2012) TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr Opin Virol 2: 142–150. doi: 10.1016/j.coviro.2012.02.003 22482711
59. Sokolskaja E, Berthoux L, Luban J, (2006) Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 80: 2855–2862. doi: 10.1128/JVI.80.6.2855–2862.2006 16501094
60. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, et al. (2003) Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 9: 1138–1143. doi: 10.1038/nm910 12897779
61. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, et al. (2003) As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol 77: 3167–3180. 12584341
62. Saenz DT, Teo W, Olsen JC, Poeschla EM, (2005) Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins. J Virol 79: 15175–15188. doi: 10.1128/JVI.79.24.15175–15188.2005 16306589
63. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, et al. (2009) Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 5: e1000546. doi: 10.1371/journal.ppat.1000546 19680534
64. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ, (2005) A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 102: 13212–13217. doi: 10.1073/pnas.0506306102 16141338
65. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP, (1993) Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73: 1067–1078. 8513493
66. Berthoux L, Sebastian S, Sokolskaja E, Luban J, (2005) Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci USA 102: 14849–14853. doi: 10.1073/pnas.0505659102 16203999
67. Neagu MR, Ziegler P, Pertel T, Strambio de Castillia C, Grütter C, et al. (2009) Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest 119: 3035–3047. doi: 10.1172/JCI39354 19741300
68. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, et al. (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 6: 1808–1818. doi: 10.1038/sj.gt.3301023 10602376
69. Butler SL, Hansen MS, Bushman FD, (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631–634. doi: 10.1038/87979 11329067
70. De Iaco A, Luban J, (2011) Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology 8: 98. doi: 10.1186/1742-4690-8-98 22145813
71. Liu GE, Alkan C, Jiang L, Zhao S, Eichler EE, (2009) Comparative analysis of Alu repeats in primate genomes. Genome Res 19: 876–885. doi: 10.1101/gr.083972.108 19411604
72. De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, et al. (2013) TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology 10: 20. doi: 10.1186/1742-4690-10-20 23414560
73. Morozova KS, Piatkevich KD, Gould TJ, Zhang J, Bewersdorf J, et al. (2010) Far-red fluorescent protein excitable with red lasers for flow cytometry and superresolution STED nanoscopy. Biophys J 99: L13–L15. doi: 10.1016/j.bpj.2010.04.025 20643047
74. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, et al. (2010) A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467: 214–217. doi: 10.1038/nature09337 20829794
75. Simon JH, Gaddis NC, Fouchier RA, Malim MH, (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4: 1397–1400. doi: 10.1038/3987 9846577
76. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P, (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci USA 100: 15154–15159. doi: 10.1073/pnas.2433165100 14657387
77. Bates P, Young JA, Varmus HE, (1993) A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor. Cell 74: 1043–1051. 8402880
78. Schmitz C, Marchant D, Neil SJD, Aubin K, Reuter S, et al. (2004) Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol 78: 2006–2016. 14747565
79. Pineda MJ, Orton BR, Overbaugh J, (2007) A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. Virology 363: 310–318. doi: 10.1016/j.virol.2007.02.002 17350067
80. McKnight A, Griffiths DJ, Dittmar M, Clapham P, Thomas E, (2001) Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. J Virol 75: 6914–6922. doi: 10.1128/JVI.75.15.6914–6922.2001 11435571
81. Boone LR, Innes CL, Heitman CK, (1990) Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J Virol 64: 3376–3381. 1693703
82. Towers G, Collins M, Takeuchi Y, (2002) Abrogation of Ref1 retrovirus restriction in human cells. J Virol 76: 2548–2550. 11836433
83. Kahl CA, Cannon PM, Oldenburg J, Tarantal AF, Kohn DB, (2008) Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors. Gene Ther 15: 1079–1089. doi: 10.1038/gt.2008.50 18385767
84. Logue EC, Taylor KT, Goff PH, Landau NR, (2011) The cargo-binding domain of transportin 3 is required for lentivirus nuclear import. J Virol 85: 12950–12961. doi: 10.1128/JVI.05384-11 21976643
85. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481–485. doi: 10.1038/nature09907 21478870
86. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, et al. (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275: 36062–36066. doi: 10.1074/jbc.M007204200 10967126
87. Uchil PD, Quinlan BD, Chan W-T, Luna JM, Mothes W, (2008) TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4: e16. doi: 10.1371/journal.ppat.0040016 18248090
88. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD, (2005) Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 79: 15567–15572. doi: 10.1128/JVI.79.24.15567–15572.2005 16306627
89. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, et al. (2010) Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7: 221–233. doi: 10.1016/j.chom.2010.02.007 20227665
90. Pryciak PM, Varmus HE, (1992) Fv-1 restriction and its effects on murine leukemia virus integration in vivo and in vitro. J Virol 66: 5959–5966. 1326652
91. Burdick RC, Hu W-S, Pathak VK, (2013) Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes. Proceedings of the National Academy of Sciences 110: E4780–E4789. doi: 10.1073/pnas.1315996110
92. Yamashita M, Perez O, Hope TJ, Emerman M, (2007) Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog 3: 1502–1510. doi: 10.1371/journal.ppat.0030156 17967060
93. De Iaco A, Luban J, (2014) Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA. Retrovirology 11: 11. doi: 10.1186/1742-4690-11-11 24479545
94. de Silva TI, Cotten M, Rowland-Jones SL, (2008) HIV-2: the forgotten AIDS virus. Trends Microbiol 16: 588–595. doi: 10.1016/j.tim.2008.09.003 18964021
95. He J, Chen Y, Farzan M, Choe H, Ohagen A, et al. (1997) CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385: 645–649. doi: 10.1038/385645a0 9024664
96. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, et al. (1987) Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326: 662–669. doi: 10.1038/326662a0 3031510
97. Miyamoto T, Nakayama EE, Yokoyama M, Ibe S, Takehara S, et al. (2012) The Carboxyl-Terminus of Human Immunodeficiency Virus Type 2 Circulating Recombinant form 01_AB Capsid Protein Affects Sensitivity to Human TRIM5α. PLoS ONE 7: e47757. doi: 10.1371/journal.pone.0047757 23094081
98. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D, (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871–875. doi: 10.1038/nbt0997-871 9306402
99. Bock M, Bishop KN, Towers G, Stoye JP, (2000) Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 74: 7422–7430. 10906195
100. Harrison IP, McKnight A, (2011) Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2. Virology 415: 47–55. doi: 10.1016/j.virol.2011.04.001 21514617
101. Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, et al. (1995) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314–6322. 7666532
102. Zingler K, Bélanger CA, Peters R, Agard E, Young JA, (1995) Identification and characterization of the viral interaction determinant of the subgroup A avian leukosis virus receptor. J Virol 69: 4261–4266. 7769686
103. Boerger AL, Snitkovsky S, Young JA, (1999) Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci USA 96: 9867–9872. 10449786
104. Berthoux L, Sebastian S, Sayah DM, Luban J, (2005) Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol 79: 7883–7888. doi: 10.1128/JVI.79.12.7883–7888.2005 15919943
105. Sokolskaja E, Sayah DM, Luban J, (2004) Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 78: 12800–12808. doi: 10.1128/JVI.78.23.12800–12808.2004 15542632
106. Braaten D, Franke EK, Luban J, (1996) Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol 70: 4220–4227. 8676442
107. Sebastian S, Grütter C, Strambio de Castillia C, Pertel T, Olivari S, et al. (2009) An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding. J Virol 83: 3365–3373. doi: 10.1128/JVI.00432-08 19153241
108. Pizzato M, Erlwein O, Bonsall D, Kaye S, Muir D, et al. (2009) A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods 156: 1–7. doi: 10.1016/j.jviromet.2008.10.012 19022294
109. Vermeire J, Naessens E, Vanderstraeten H, Landi A, Iannucci V, et al. (2012) Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. PLoS ONE 7: e50859. doi: 10.1371/journal.pone.0050859 23227216